The early March approval of a new cardioprotective claim for Novo Nordisk A/S’s obesity drug Wegovy (semaglutide) could mean up to four million users of the drug in the Medicare Part D program, the company noted during its 2 May earnings call.
Wegovy's Medicare Part D Prospects: Four Million Lives And Counting?
Novo Nordisk is expecting a relatively modest uptake in Medicare Part D for the cardiovascular claim, but plans still will worry about stemming demand in obesity.
More from Market Access
More from Pink Sheet
• By
Vaccine developers should be aware that the framework underpinning the new EU Health Technology Assessment (HTA) Regulation might not be suitable for immunizations, but actions from policymakers and industry could help mitigate some issues, a senior figure from GSK says.
• By
Bavarian Nordic's Vimkunya added the US CDC immunization committee's recommendation to its FDA approval, while Valneva's Ixchiq faces a precaution for use in people aged 65 and older.
• By
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.